Home › Research › Treatments
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
Kristian Steen Frederiksen, Merçé Boada, Bruno Dubois, Sebastiaan Engelborghs, Giovanni Battista Frisoni, Jean Georges, Jakub Hort, Linus Jönsson et al.. Alzheimer s Research & Therapy, 2025-05-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies. Anti-amyloid antibodies are regarded as a substantial innovation with an important clinical impact. In addition, however, new compounds with other mechanisms of action and/or route of administration are also needed. Approval of new treatments will require changes to existing patient pathways and real-world data needs to be generated. Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval. Emphasis is placed on the necessity of regularly updating recommendations as new evidence emerges in the coming years.
What this study adds
Evidence grade: Low
Individual members of the European Alzheimer's Disease Consortium issued 24 recommendations on how anti-amyloid antibody therapy could be introduced in Europe if approved, including effects on health care systems and diagnostic pathways. They call the antibodies a substantial innovation but also say new compounds with other mechanisms are needed and recommendations must be updated as evidence emerges.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Frederiksen, K. S., Boada, M., Dubois, B., Engelborghs, S., Frisoni, G. B., Georges, J., et al. (2025). Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01766-y
Vancouver
Frederiksen KS, Boada M, Dubois B, Engelborghs S, Frisoni GB, Georges J, et al. Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01766-y. PMID: 40413561.
BibTeX
@article{frederiksen2025-40413561,
author = {Frederiksen, Kristian Steen and Boada, Merçé and Dubois, Bruno and Engelborghs, Sebastiaan and Frisoni, Giovanni Battista and Georges, Jean and Hort, Jakub and Jönsson, Linus and others},
title = {{Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC}},
journal = {Alzheimer s Research \& Therapy},
year = {2025},
doi = {10.1186/s13195-025-01766-y},
pmid = {40413561},
url = {https://doi.org/10.1186/s13195-025-01766-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies.
- Anti-amyloid antibodies are regarded as a substantial innovation with an important clinical impact.
- In addition, however, new compounds with other mechanisms of action and/or route of administration are also needed.
- Approval of new treatments will require changes to existing patient pathways and real-world data needs to be generated.
- Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval.
Why it matters
Individual members of the European Alzheimer's Disease Consortium issued 24 recommendations on how anti-amyloid antibody therapy could be introduced in Europe if approved, including effects on health care systems and diagnostic pathways. They call the antibodies a substantial innovation but also say new compounds with other mechanisms are needed and recommendations must be updated as evidence emerges.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Lutz Froelich: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 40 institution(s) in 15 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40413561) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-025-01766-y
- PubMed: 40413561
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Related studies in Treatments from nearby years
Also in Treatments
194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.